Cancer Research and Treatment

Case Report

A Case of Metastatic Low-Grade Endometrial Stromal Sarcoma Treated with Letrozole after Ovarian Ablation by Radiotherapy: Kyung Ho Yang, Jung A Shin, Joo Hyuk Jung, Hae Won Jung, Hye Ran Lee, Sunhee Chang, Ji Yeon Park, Seong Yoon Yi; Cancer Res Treat. 2015;47(4):958-962. Published online February 17, 2015; DOI: https://doi.org/10.4143/crt.2014.154

A 50-year-old woman was admitted to our hospital due to multiple lung nodules detected incidentally on a chest X-ray. A video-assisted thoracoscopic lung biopsy revealed low-grade endometrial stromal sarcoma (LG-ESS). She had undergone a simple hysterectomy 1 year earlier owing to a diagnosis of adenomyosis. A review of her previous hysterectomy specimen showed not endometriosis but LG-ESS. According to the patient’s levels of serum follicle stimulating hormone and estradiol, she was in the premenopausal state with retained and normally functioning ovaries. She then underwent ovarian ablation by radiotherapy, after which she was administered 2.5 mg of letrozole once per day. Three months later, the size of the metastatic nodules in both lungs had decreased. The patient was followed up for 24 months while continuing on letrozole, and maintained a partial remission. We report herein on a case of metastatic LG-ESS treated with letrozole after ovarian ablation by radiotherapy.

Citations

Citations to this article as recorded by

Preoperative Diagnosis and Chemotherapy of Endometrial Stromal Sarcoma with Ultrasound Image Based on Nano Bubble
Jingjing Bi, Guoyun Li, Juan Chen, Ying Yang, Cimei Li
Journal of Biomedical Nanotechnology.2023; 19(1): 117. CrossRef
Long-Term Outcome of Aromatase Inhibitor Therapy With Letrozole in Patients With Advanced Low-Grade Endometrial Stromal Sarcoma
Munekage Yamaguchi, Chimeddulam Erdenebaatar, Fumitaka Saito, Takeshi Motohara, Yo Miyahara, Hironori Tashiro, Hidetaka Katabuchi
International Journal of Gynecological Cancer.2015; 25(9): 1645. CrossRef

12,137 View
116 Download
3 Web of Science
2 Crossref

Original Article

Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea: Juan Zhou, San-Gang Wu, Jun-Jie Wang, Jia-Yuan Sun, Feng-Yan Li, Qin Lin, Huan-Xin Lin, Zhen-Yu He; Cancer Res Treat. 2015;47(1):55-63. Published online August 21, 2014; DOI: https://doi.org/10.4143/crt.2013.165

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to assess the value of ovarian ablation using goserelin in premenopausal patients with stage II/III hormone receptor-positive breast cancer without chemotherapy-induced amenorrhea (CIA). Materials and Methods We retrospectively reviewed the data of breast patients treated between October 1999 and November 2007 without CIA. The Kaplan-Meier method was used for calculation of the survival rate. Log rank method and Cox regression analysis were used for univariate and multivariate prognostic analysis. Results The median follow-up period was 61 months. Initially, 353 patients remained without CIA after chemotherapy and 98 among those who received goserelin and tamoxifen (TAM). In univariate analysis, goserelin improved locoregional recurrence-free survival (LRFS) (98.9% vs. 94.1%, p=0.041), distant metastasis-free survival (DMFS) (85.4% vs. 71.9%, p=0.006), disease-free survival (DFS) (85.4% vs. 71.6%, p=0.005), and overall survival (OS) (93.5% vs. 83.5%, p=0.010). In multivariate analysis, goserelin treatment was an independent factor influencing DMFS (hazard ratio [HR], 1.603; 95% confidence interval [CI], 1.228 to 2.092; p=0.001), DFS (HR, 1.606; 95% CI, 1.231 to 2.096; p=0.001), and OS (HR, 3.311; 95% CI, 1.416 to 7.742; p=0.006). In addition, treatment with goserelin resulted in significantly improved LRFS (p=0.039), DMFS (p=0.043), DFS (p=0.036), and OS (p=0.010) in patients aged < 40 years. In patients aged ≥ 40 years, goserelin only improved DMFS (p=0.028) and DFS (p=0.027). Conclusion Ovarian ablation with goserelin plus TAM resulted in significantly improved therapeutic efficacy in premenopausal patients with stage II/III hormone receptor-positive breast cancer without CIA.

Citations

Citations to this article as recorded by

An updated systematic review about various effects of microplastics on cancer: A pharmacological and in-silico based analysis
Akmaral Baspakova, Afshin Zare, Roza Suleimenova, Aidar B. Berdygaliev, Bibigul Karimsakova, Kymbat Tussupkaliyeva, Nadiar M. Mussin, Kulyash R. Zhilisbayeva, Nader Tanideh, Amin Tamadon
Molecular Aspects of Medicine.2025; 101: 101336. CrossRef
Adjuvant ovarian function suppression and tamoxifen in premenopausal breast cancer patients: A meta-analysis
Hamdy A. Azim, Kyrillus S. Shohdy, David F. Kaldas, Loay Kassem, Hatem A. Azim
Current Problems in Cancer.2020; 44(6): 100592. CrossRef
Feasibility and efficacy of ultrasonographic and laparoscopic guidance for microwave ablation of clinically normal canine ovaries
Valentine D. Verpaalen, J. Brad Case, Michael J. Dark, S. Joel Cardenas-Goicoechea, Matt D. Winter, Sarah E. Boston, Fernando Garcia-Pereira, Alice S. Rhoton-Vlasak, Beau B. Toskich
American Journal of Veterinary Research.2020; 81(9): 747. CrossRef
Breast cancer in young patients. Peculiarities of prognosis and adjuvant hormone therapy (a literature review)
D. N. Kravchenko, A. A. Parokonnaya, M. I. Nechushkin, E. A. Nikitina, N. D. Hakurinova
Tumors of female reproductive system.2018; 14(3): 55. CrossRef
Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer
Lin Qiu, Fangmeng Fu, Meng Huang, Yuxiang Lin, Yazhen chen, Minyan Chen, Chuan Wang
Scientific Reports.2016;[Epub] CrossRef
Evaluation of a Survivorship Care Plan: Long-Term Use, Care Coordination and Quality of Life in Breast Cancer Survivors
Meagan E Brennan, Frances M Boyle, Phyllis N Butow, Andrew J Spillane
Breast Cancer Management.2015; 4(3): 145. CrossRef
More Options for Fertility Preservation for Patients With Cancer
Pamela N. Munster
Journal of Clinical Oncology.2015; 33(22): 2413. CrossRef

13,066 View
117 Download
8 Web of Science
7 Crossref

First
Prev
Page of 1
Next
Last

Search